Literature DB >> 26246672

SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.

Edward C Chao.   

Abstract

Glucosuria, the presence of glucose in the urine, has long been regarded as a consequence of uncontrolled diabetes. However, glucose excretion can be induced by blocking the activity of the renal sodium-glucose cotransporter 2 (SGLT-2). This mechanism corrects hyperglycemia independently of insulin. This article provides an overview of the paradigm shift that triggered the development of the SGLT-2 inhibitor class of agents and summarizes the available evidence from clinical studies to date.

Entities:  

Year:  2014        PMID： 26246672      PMCID： PMC4521423          DOI： 10.2337/diaclin.32.1.4

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


  58 in total

Review 1.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

2.  Sodium-glucose transporter-2 inhibition as an antidiabetic therapy.

Authors:  Ele Ferrannini
Journal:  Nephrol Dial Transplant       Date:  2010-05-02       Impact factor: 5.992

3.  Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

Authors:  C J Bailey; N Iqbal; C T'joen; J F List
Journal:  Diabetes Obes Metab       Date:  2012-07-24       Impact factor: 6.577

4.  Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects.

Authors:  C E Mogensen
Journal:  Scand J Clin Lab Invest       Date:  1971-09       Impact factor: 1.713

5.  Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.

Authors:  J Rosenstock; L J Seman; A Jelaska; S Hantel; S Pinnetti; T Hach; H J Woerle
Journal:  Diabetes Obes Metab       Date:  2013-08-22       Impact factor: 6.577

6.  Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

Authors:  D Devineni; L Morrow; M Hompesch; D Skee; A Vandebosch; J Murphy; K Ways; S Schwartz
Journal:  Diabetes Obes Metab       Date:  2012-02-08       Impact factor: 6.577

Review 7.  Solute carrier family 2, member 9 and uric acid homeostasis.

Authors:  Chris Cheeseman
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-09       Impact factor: 2.894

8.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.

Authors:  N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh
Journal:  Lancet       Date:  2010-06-26       Impact factor: 202.731

9.  Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.

Authors:  Ralph A Defronzo
Journal:  Diabetes       Date:  2009-04       Impact factor: 9.461

Review 10.  Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.

Authors:  J E Gerich
Journal:  Diabet Med       Date:  2010-02       Impact factor: 4.359
View more
  33 in total

1.  Tofogliflozin: first global approval.

Authors:  Raewyn M Poole; Jennifer E Prossler
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

Review 2.  Naturally Occurring SGLT2 Inhibitors: A Review.

Authors:  Habib Yaribeygi; Milad Ashrafizadeh; Thozhukat Sathyapalan; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Renal cell markers: lighthouses for managing renal diseases.

Authors:  Shivangi Agarwal; Yashwanth R Sudhini; Onur K Polat; Jochen Reiser; Mehmet M Altintas
Journal:  Am J Physiol Renal Physiol       Date:  2021-10-11

Review 4.  Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs.

Authors:  Carolin Thomas; Lia Wurzer; Ernst Malle; Michael Ristow; Corina T Madreiter-Sokolowski
Journal:  Front Aging       Date:  2022-06-14

5.  Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.

Authors:  Atsuo Tahara; Toshiyuki Takasu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-01-26       Impact factor: 3.000

Review 6.  Looking back and thinking forwards - 15 years of cardiology and cardiovascular research.

Authors:  Jonathan M Kalman; Sergio Lavandero; Felix Mahfoud; Matthias Nahrendorf; Magdi H Yacoub; Dong Zhao
Journal:  Nat Rev Cardiol       Date:  2019-09-30       Impact factor: 32.419

7.  Biochemical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors by Cardiovascular Risk Profile and Volume Status in a Real-World Diabetic Population.

Authors:  Mauro Gitto; Alexios S Kotinas; Riccardo Terzi; Angelo Oliva; Jorgele Zagoreo; Bernhard Reimers; Giulio G Stefanini; Marco Mirani; Giuseppe Favacchio; Gianluigi Condorelli; Cristina Panico
Journal:  J Cardiovasc Pharmacol       Date:  2022-07-01       Impact factor: 3.271

8.  Recommendations for management of diabetes during Ramadan: update 2015.

Authors:  Mahmoud Ibrahim; Megahed Abu Al Magd; Firas A Annabi; Samir Assaad-Khalil; Ebtesam M Ba-Essa; Ibtihal Fahdil; Sehnaz Karadeniz; Terry Meriden; Aly A Misha'l; Paolo Pozzilli; Samad Shera; Abraham Thomas; Suhad Bahijri; Jaakko Tuomilehto; Temel Yilmaz; Guillermo E Umpierrez
Journal:  BMJ Open Diabetes Res Care       Date:  2015-06-16

Review 9.  The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies.

Authors:  Melanie Davies; Sudesna Chatterjee; Kamlesh Khunti
Journal:  Clin Pharmacol       Date:  2016-06-23

10.  Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.

Authors:  Christina Kohlmorgen; Stephen Gerfer; Kathrin Feldmann; Sören Twarock; Sonja Hartwig; Stefan Lehr; Meike Klier; Irena Krüger; Carolin Helten; Petra Keul; Sabine Kahl; Amin Polzin; Margitta Elvers; Ulrich Flögel; Malte Kelm; Bodo Levkau; Michael Roden; Jens W Fischer; Maria Grandoch
Journal:  Diabetologia       Date:  2021-06-16       Impact factor: 10.122
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.